131 related articles for article (PubMed ID: 2748880)
1. Consequences of monoamine oxidase inhibition: increased vesicular accumulation of dopamine and norepinephrine and increased metabolism by catechol-O-methyltransferase and phenolsulfotransferase.
Buu NT; Lussier C
Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(3-4):563-8. PubMed ID: 2748880
[TBL] [Abstract][Full Text] [Related]
2. Relationship between catechol-O-methyltransferase and phenolsulfotransferase in the metabolism of dopamine in the rat brain.
Buu NT
J Neurochem; 1985 Nov; 45(5):1612-9. PubMed ID: 3930664
[TBL] [Abstract][Full Text] [Related]
3. Modification of dopamine and norepinephrine metabolism in the rat brain by monoamine oxidase inhibitors.
Buu NT; Angers M; Duhaime J; Kuchel O
J Neural Transm; 1987; 70(1-2):39-50. PubMed ID: 3668521
[TBL] [Abstract][Full Text] [Related]
4. Effects of different monoamine oxidase inhibitors on the metabolism of L-dopa in the rat brain.
Nguyen TB; Angers M
Biochem Pharmacol; 1987 May; 36(10):1731-5. PubMed ID: 3109430
[TBL] [Abstract][Full Text] [Related]
5. Vesicular accumulation of dopamine following L-DOPA administration.
Buu NT
Biochem Pharmacol; 1989 Jun; 38(11):1787-92. PubMed ID: 2735936
[TBL] [Abstract][Full Text] [Related]
6. Modification of vesicular dopamine and norepinephrine by monoamine oxidase inhibitors.
Buu NT
Biochem Pharmacol; 1989 May; 38(10):1685-92. PubMed ID: 2730683
[TBL] [Abstract][Full Text] [Related]
7. Handling of dopamine and dopamine sulfate by isolated perfused rat kidney.
Buu NT; Duhaime J; Kuchel O
Am J Physiol; 1986 Jun; 250(6 Pt 2):F975-9. PubMed ID: 3717353
[TBL] [Abstract][Full Text] [Related]
8. Effect of high single doses of levodopa and carbidopa on brain dopamine and its metabolites: modulation by selective inhibitors of monoamine oxidase and/or catechol-O-methyltransferase in the male rat.
Männistö PT; Tuomainen P
Naunyn Schmiedebergs Arch Pharmacol; 1991 Oct; 344(4):412-8. PubMed ID: 1766471
[TBL] [Abstract][Full Text] [Related]
9. L-dopa metabolism in genetically hypertensive mice: effect of pargyline.
Buu NT; Duhaime J; Racz K; Kuchel O; Schlager G
Can J Physiol Pharmacol; 1987 Dec; 65(12):2390-5. PubMed ID: 3449195
[TBL] [Abstract][Full Text] [Related]
10. Comparison of short and long-lasting effects of pargyline on cerebral dopamine metabolism.
Waldmeier PC; Maître L
Naunyn Schmiedebergs Arch Pharmacol; 1976 Aug; 294(2):133-40. PubMed ID: 1012333
[TBL] [Abstract][Full Text] [Related]
11. The contribution by monoamine oxidase and catechol-O-methyltransferase to the total-body and pulmonary plasma clearance of catecholamines.
Friedgen B; Wölfel R; Graefe KH
Naunyn Schmiedebergs Arch Pharmacol; 1996 Jan; 353(2):193-9. PubMed ID: 8717160
[TBL] [Abstract][Full Text] [Related]
12. Contribution of sulfate conjugation, deamination, and O-methylation to metabolism of dopamine and norepinephrine in human brain.
Rivett AJ; Eddy BJ; Roth JA
J Neurochem; 1982 Oct; 39(4):1009-16. PubMed ID: 6956674
[TBL] [Abstract][Full Text] [Related]
13. 3-Methoxytyramine and normetanephrine as indicators of dopamine and noradrenaline release in mouse brain in vivo.
Kehr W
J Neural Transm; 1981; 50(2-4):165-78. PubMed ID: 7241115
[TBL] [Abstract][Full Text] [Related]
14. 3-Methoxytyramine formation following monoamine oxidase inhibition is a poor index of dendritic dopamine release in the substantia nigra.
Elverfors A; Pileblad E; Lagerkvist S; Bergquist F; Jonason J; Nissbrandt H
J Neurochem; 1997 Oct; 69(4):1684-92. PubMed ID: 9326297
[TBL] [Abstract][Full Text] [Related]
15. Metabolism of centrally released noradrenaline by extraneuronal monoamine oxidase and catechol-O-methyltransferase.
Van Wijk M; Korf J
Brain Res; 1976 Apr; 106(2):403-6. PubMed ID: 1276880
[No Abstract] [Full Text] [Related]
16. A new and highly sensitive method for measuring 3-methoxytyramine using HPLC with electrochemical detection. Studies with drugs which alter dopamine metabolism in the brain.
Heal DJ; Frankland AT; Buckett WR
Neuropharmacology; 1990 Dec; 29(12):1141-50. PubMed ID: 2293058
[TBL] [Abstract][Full Text] [Related]
17. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.
Parada A; Loureiro AI; Vieira-Coelho MA; Hainzl D; Soares-da-Silva P
Eur J Pharmacol; 2001 May; 420(1):27-32. PubMed ID: 11412836
[TBL] [Abstract][Full Text] [Related]
18. Lack of effect of corticotropin releasing factor on hypothalamic dopamine and serotonin synthesis turnover rates in rats.
Van Loon GR; Shum A; Ho D
Peptides; 1982; 3(5):799-803. PubMed ID: 6294636
[TBL] [Abstract][Full Text] [Related]
19. Studies on the acute and long-term changes in dopamine and noradrenaline metabolism in mouse brain following administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Pileblad E; Carlsson A
Pharmacol Toxicol; 1988 Apr; 62(4):213-22. PubMed ID: 3260379
[TBL] [Abstract][Full Text] [Related]
20. Vesicular and ganglionic norepinephrine in the rat: progressive increase with age.
Buu NT; Debinski W
J Neurochem; 1990 Feb; 54(2):620-6. PubMed ID: 2299355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
